<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03103282</url>
  </required_header>
  <id_info>
    <org_study_id>PuraStat-002-VASC</org_study_id>
    <nct_id>NCT03103282</nct_id>
  </id_info>
  <brief_title>Post-market Clinical Study to Confirm Safety and Performance of PuraStat® for the Management of Bleeding in Vascular Surgery.</brief_title>
  <official_title>A Multi-center, Single Arm Post-market Clinical Study to Confirm Safety and Performance of PuraStat® Absorbable Haemostatic Material for the Management of Bleeding In Vascular Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>3-D Matrix Europe SAS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>3-D Matrix Europe SAS</source>
  <brief_summary>
    <textblock>
      The objective of this post-market clinical follow-up study is to collect medical information&#xD;
      on patients implanted with PuraStat®, according to each participating institution's&#xD;
      procedures and standards of care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multicentre, single arm post-market clinical study aims to collect medical information&#xD;
      on patients implanted with PuraStat®, Absorbable Haemostatic Material, according to each&#xD;
      participating institution's procedures and standards of care for confirming the safety and&#xD;
      the performance of PuraStat®, for the management of bleeding in vascular surgery (Carotid&#xD;
      Endarterectomy either by direct closure (without the use of patch), or by patch&#xD;
      reconstruction or eversion technique).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 14, 2017</start_date>
  <completion_date type="Actual">August 30, 2019</completion_date>
  <primary_completion_date type="Actual">July 5, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Total Time-To-Haemostasis</measure>
    <time_frame>Intraoperatively</time_frame>
    <description>Total Time-To-Haemostasis (TTH) will be intraoperatively measured (secondes) from the first application of PuraStat® to a bleeding site after clamp release, until all bleeding at that site has ceased. In case of rebleeding of the treated sites and additional application of PuraStat®, the TTH will be calculated by the addition of TTH1+ TTH(n+1), where TTH1+ TTH(n+1) are the time to haemostasis after each application of PuraStat®.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Status Post Application(s)</measure>
    <time_frame>Intraoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Loss</measure>
    <time_frame>Intraoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Drainage Volume</measure>
    <time_frame>Post-operatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion of Blood Products</measure>
    <time_frame>Intraoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion of Blood Products</measure>
    <time_frame>Post-operatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of Blood Product(s) and or Substitute(s)</measure>
    <time_frame>Intraoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Product Use</measure>
    <time_frame>Intraoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>Discharge</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">65</enrollment>
  <condition>Vascular Anastomosis Surgery</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PuraStat®</intervention_name>
    <description>Synthetic haemostatic material</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients scheduled for elective carotid endarterectomy and who have been treated with&#xD;
        PuraStat®&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Main Inclusion criteria:&#xD;
&#xD;
          1. Male or female patient ≥18 years old&#xD;
&#xD;
          2. Subject undergoing elective carotid endarterectomy&#xD;
&#xD;
          3. Subject who is able to give voluntary, written informed consent to participate in this&#xD;
             clinical study and from whom consent has been obtained&#xD;
&#xD;
          4. Subject, who, in the opinion of the Clinical Investigator, is able to understand this&#xD;
             clinical study, cooperate with the study procedures and is willing to return for the&#xD;
             required post-treatment follow-up&#xD;
&#xD;
          5. Intra-operative inclusion criteria: Subject requiring the use of PuraStat® for&#xD;
             haemostasis during elective carotid endarterectomy either by direct closure (without&#xD;
             the use of patch), or by patch reconstruction or eversion technique when haemostasis&#xD;
             by ligation or standard means is insufficient or impractical.&#xD;
&#xD;
        Main exclusion criteria:&#xD;
&#xD;
          1. Presence or sequelae of coagulation disorder&#xD;
&#xD;
          2. Known allergy or hypersensitivity to any component of PuraStat®&#xD;
&#xD;
          3. Concurrent participation in another clinical trial with a medical device or a&#xD;
             medicinal product&#xD;
&#xD;
          4. Pregnant or interested in becoming pregnant during the duration of the study, or&#xD;
             breast feeding&#xD;
&#xD;
             Intra-operative exclusion criteria:&#xD;
&#xD;
          5. Spurting and/or gushing haemorrhage site(s)&#xD;
&#xD;
          6. Contaminated or potentially contaminated surgical area&#xD;
&#xD;
          7. Fibrin glue and/or topical haemostatic agent used before or concomitantly to the use&#xD;
             of PuraStat®&#xD;
&#xD;
          8. Persistent major bleeding after conventional haemostasis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>St George'S University Hospitals Nhs Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>March 31, 2017</study_first_submitted>
  <study_first_submitted_qc>March 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2017</study_first_posted>
  <results_first_submitted>November 13, 2020</results_first_submitted>
  <results_first_submitted_qc>November 13, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 10, 2020</results_first_posted>
  <last_update_submitted>November 13, 2020</last_update_submitted>
  <last_update_submitted_qc>November 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 2, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT03103282/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 19, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT03103282/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PuraStat®</title>
          <description>Adult patients scheduled for elective carotid endarterectomy and who have been treated with PuraStat®</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PuraStat®</title>
          <description>Adult patients scheduled for elective carotid endarterectomy and who have been treated with PuraStat®</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="65"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.8" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Time-To-Haemostasis</title>
        <description>Total Time-To-Haemostasis (TTH) will be intraoperatively measured (secondes) from the first application of PuraStat® to a bleeding site after clamp release, until all bleeding at that site has ceased. In case of rebleeding of the treated sites and additional application of PuraStat®, the TTH will be calculated by the addition of TTH1+ TTH(n+1), where TTH1+ TTH(n+1) are the time to haemostasis after each application of PuraStat®.</description>
        <time_frame>Intraoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PuraStat®</title>
            <description>Adult patients scheduled for elective carotid endarterectomy and who have been treated with PuraStat® in heparin or other antiplatelet treatments during the procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Time-To-Haemostasis</title>
          <description>Total Time-To-Haemostasis (TTH) will be intraoperatively measured (secondes) from the first application of PuraStat® to a bleeding site after clamp release, until all bleeding at that site has ceased. In case of rebleeding of the treated sites and additional application of PuraStat®, the TTH will be calculated by the addition of TTH1+ TTH(n+1), where TTH1+ TTH(n+1) are the time to haemostasis after each application of PuraStat®.</description>
          <units>Secondes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" spread="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Status Post Application(s)</title>
        <time_frame>Intraoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PuraStat®</title>
            <description>Adult patients scheduled for elective carotid endarterectomy and who have been treated with PuraStat® in heparin or other antiplatelet treatments during the procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Status Post Application(s)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete Haemostasis</title>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Presence of bleeding</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Loss</title>
        <time_frame>Intraoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PuraStat®</title>
            <description>Adult patients scheduled for elective carotid endarterectomy and who have been treated with PuraStat® in heparin or other antiplatelet treatments during the procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Loss</title>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.0" spread="111.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Drainage Volume</title>
        <time_frame>Post-operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PuraStat®</title>
            <description>Adult patients scheduled for elective carotid endarterectomy and who have been treated with PuraStat® in heparin or other antiplatelet treatments during the procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Drainage Volume</title>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.1" spread="50.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transfusion of Blood Products</title>
        <time_frame>Intraoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PuraStat®</title>
            <description>Adult patients scheduled for elective carotid endarterectomy and who have been treated with PuraStat® in heparin or other antiplatelet treatments during the procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Transfusion of Blood Products</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>YES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transfusion of Blood Products</title>
        <time_frame>Post-operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PuraStat®</title>
            <description>Adult patients scheduled for elective carotid endarterectomy and who have been treated with PuraStat® in heparin or other antiplatelet treatments during the procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Transfusion of Blood Products</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>NO</title>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>YES</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quantity of Blood Product(s) and or Substitute(s)</title>
        <time_frame>Intraoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PuraStat®</title>
            <description>Adult patients scheduled for elective carotid endarterectomy and who have been treated with PuraStat® in heparin or other antiplatelet treatments during the procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Quantity of Blood Product(s) and or Substitute(s)</title>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="580.0" spread="113.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Product Use</title>
        <time_frame>Intraoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PuraStat®</title>
            <description>Adult patients scheduled for elective carotid endarterectomy and who have been treated with PuraStat® in heparin or other antiplatelet treatments during the procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Product Use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ease of preparation</title>
              <category_list>
                <category>
                  <title>Excellent</title>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Good</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fair</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Poor</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ease of application</title>
              <category_list>
                <category>
                  <title>Excellent</title>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Good</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fair</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Poor</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Hospital Stay</title>
        <time_frame>Discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PuraStat®</title>
            <description>Adult patients scheduled for elective carotid endarterectomy and who have been treated with PuraStat® in heparin or other antiplatelet treatments during the procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Hospital Stay</title>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>At procedure, 1 day post-operative, 5-7 days post-operative, 1 month (± 15 days) post-operative</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PuraStat®</title>
          <description>Adult patients scheduled for elective carotid endarterectomy and who have been treated with PuraStat® in heparin or other antiplatelet treatments during the procedure.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <description>Events are not related to PuraStat®</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Events are not related to PuraStat®</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Events are not related to PuraStat®</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <description>Events are not related to PuraStat®</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <description>Events are not related to PuraStat®</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3.1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage/Haematoma</sub_title>
                <description>AEs are related to PuraStat®</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <description>AEs are not related to PuraStat®</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Florian REBECA</name_or_title>
      <organization>3-D Matrix Europe SAS</organization>
      <phone>+33617587769</phone>
      <email>frebeca@puramatrix.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

